FRACTYL HEALTH, INC.
No enriched coverage for $GUTS in the last 7 days.
FRACTYL HEALTH, INC. (GUTS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 24, 2026, Fractyl Health, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). Of the 159,179,848, shares of the Company’s common stock outstanding as of the record date
BRADLEY WILLIAM purchased 64,516 shares of FRACTYL HEALTH, INC. (GUTS) at $0.62 on 2026-09-14.
Fractyl Health (GUTS) presented at the Morgan Stanley Healthcare Conference, highlighting Revita, a procedure designed to help patients maintain weight loss after stopping GLP-1 drugs. The company expects pivotal trial data in early Q4 2024, with pilot studies showing promising results. Fractyl plans a focused launch through 100-200 bariatric centers, aiming for U.S. clearance by late 2027. Shares have fallen 72% year-to-date, but analysts see upside potential with price targets ranging from $2
Recent GUTS coverage spans technology, earnings and corporate actions.
In the last 30 days, GUTS insiders filed 1 SEC Form 4 transaction — 1 purchase ($40K) and no sales. The most active reporter was BRADLEY WILLIAM with 1 filing.
Reverse split will reduce share count and could boost price per share, affecting liquidity and short positions.
Insider purchase suggests positive sentiment but the transaction size is modest.
Positive trial design and FDA Breakthrough Device status may support upside if data meet endpoints.
H.C. Wainwright highlighted Fractyl Health (GUTS) as a standout biotech opportunity, citing its strategic path to market for Revita treatment. The firm projects a 2028 launch and profitability within 5-8 quarters post-launch. Fractyl's Q2 results exceeded expectations with a narrower loss per share. H.C. Wainwright maintains its positive thesis based on clinical data and commercial strategy.
The pre‑market price jump reflects trader reaction to the upcoming investor event and recent positive trial data.
AlphAI scores every news story that mentions GUTS with an AI model for sentiment and relevance, and aggregates insider trades from FRACTYL HEALTH, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
FRACTYL HEALTH, INC. (GUTS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 24, 2026, Fractyl Health, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). Of the 159,179,848, shares of the Company’s common stock outstanding as of the record date
2 min readBRADLEY WILLIAM purchased 64,516 shares of FRACTYL HEALTH, INC. (GUTS) at $0.62 on 2026-09-14.
1 min readFractyl Health (GUTS) presented at the Morgan Stanley Healthcare Conference, highlighting Revita, a procedure designed to help patients maintain weight loss after stopping GLP-1 drugs. The company expects pivotal trial data in early Q4 2024, with pilot studies showing promising results. Fractyl plans a focused launch through 100-200 bariatric centers, aiming for U.S. clearance by late 2027. Shares have fallen 72% year-to-date, but analysts see upside potential with price targets ranging from $2
2 min readH.C. Wainwright highlighted Fractyl Health (GUTS) as a standout biotech opportunity, citing its strategic path to market for Revita treatment. The firm projects a 2028 launch and profitability within 5-8 quarters post-launch. Fractyl's Q2 results exceeded expectations with a narrower loss per share. H.C. Wainwright maintains its positive thesis based on clinical data and commercial strategy.
2 min readFractyl Health (GUTS) stock rose 2.8% in pre-market trading ahead of its Virtual Commercial Strategy Day, where management will discuss the commercial strategy for Revita, its procedural therapy. Recent clinical data showed patients maintained 84% of GLP-1-induced weight loss. Analysts from Bank of America and Morgan Stanley have differing ratings. The move is driven by company-specific catalysts, not broader market trends.
2 min readH.C. Wainwright analyst Joseph Pantginis reiterated a Buy/top-pick view on Fractyl Health (GUTS), citing progress in its Revita program. He expects pivotal data and a potential De Novo submission in Q4 2026. The article notes Q2 2026 EPS of -$0.16 and cash of $47.1M, and cites an $8 price target.
4 min readFRACTYL HEALTH, INC. (GUTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablation
6 min readFractyl Health reported one-year results for its Revita procedure in a 45-participant modified intention-to-treat group. Revita cut weight regain versus sham, with least-squares mean regain of 7.8% vs 13.0%. In higher-intensity duodenal ablation subgroups, it preserved about 81% to 84% of GLP-1 weight loss. Safety was similar between groups. Shares rose 19.54% to $0.85.
3 min readFractyl Health (GUTS) reported one-year randomized REMAIN-1 midpoint cohort results for its Revita duodenal mucosal resurfacing system in patients who stopped GLP-1 therapy. In 45 participants, Revita cut weight regain versus sham (7.8% vs 13.0% of body weight). Responder rates were 73% vs sham, rising to 91% with complete ablation. Stock rose to $0.80.
5 min readFractyl Health (Nasdaq: GUTS) reported one-year, randomized sham-controlled REMAIN-1 midpoint cohort results for its Revita DMR system after GLP-1 discontinuation. In mITT (N=45), weight regain was 7.8% vs 13.0% with sham. Complete duodenal ablation (>14 cm) retained ~81% vs 48% with sham. No device-related serious AEs. Next: six-month pivotal topline in early Q4 2026 and possible FDA De Novo late Q4 2026.
5 min read
